Work

KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz248.048

Authors: D.P. Petrylak, B. Li, C. Schloss, K. Fizazi

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977993386

FWCI: 0.185

Cites:

Cited by: 5

Related to: 10